Inhaled vaccines
AssigneeQuadrant Technologies Limited
InventorsCynthia Licalsi, Gary Ward, Bernard Greenspan, Clyde Witham
Life of this patent
Estimating the term…
Abstract
In a method for creating an immune response, a vaccine is prepared in the form of a dry powder. The powder particles have an aerodynamic particle size range from 1-100 microns. A dose of powder is loaded into a dry powder inhaler. The dose is inhaled with an inspiratory flow rate of less than 60 liters per minute. A mucosal immune response is created via particles of the vaccine material depositing on the upper respiratory tract. A systemic immune response is created via particles of the vaccine material depositing into the deep lung. The vaccine material is size reduced by e.g., jet milling, into the desired range, yet vaccine potency is retained.
Claims29
A method for creating an immune response in a patient, comprising the steps of:
- preparing a vaccine material as a vaccine formulation including dry powder vaccine particles, with at least 90% of the dry powder vaccine particles having an aerodynamic particle size of less than 100 microns;
- loading the vaccine formulation into a dry powder inhaler free of any propellant gas;
- and disbursing the dry powder vaccine particles and inhaling the vaccine particles, via patient inspiration at an inspiratory flow rate of less than 10 liters per minute.
A method for delivering measles vaccines comprising the steps of:
- reducing the measles vaccines to a volume of measles vaccine particles with a median diameter of from 1-5 micron;
- blending the measles vaccine particles with an excipient to form a blended formulation;
- filling a single dose of the blended formulation into a blister container;
- and sealing the blister container;
- opening the blister container at a time of delivering the measles vaccine;
- disbursing the blended formulation for inhalation via patient inspiration;
- and
- inhaling the disbursed blended formulation into the lungs of a patient;
- wherein
- the measles vaccine retains a sufficient potency to provide an immune response.
An inhaler for delivering a vaccine comprising:
- an inhaler body;
- a mouthpiece on the inhaler body;
- a dose container on or in the inhaler body;
- a dry powder formulation, including dry powder vaccine particles with at least 90% of the dry powder vaccine particles having an aerodynamic particle size of less than 100 microns, within the dose container;
- a seal on the dose container, sealing the dry powder formulation in the dose container;
- and
- the inhaler body and the mouthpiece having a flowpath therethrough, with the flowpath having a flow resistance of from 0.1-0.25 (cmH2O)½/liter per minute, to provide for powder disbursion and inhalation via patient inspiration.
A vaccine dose comprising:
- a vaccine material as a vaccine formulation including dry powder vaccine particles, with at least 90% of the dry powder vaccine particles having an aerodynamic particle size of less than 100 microns;
- and
- the vaccine dose having a weight of from 3-25 mg, with the vaccine dose contained in a sealed container adapted to be opened with the use of a dry powder inhaler, to allow a user to inhale the dose.
A method for creating an immune response in a patient, comprising the steps of:
- preparing a vaccine material as a vaccine formulation including dry powder vaccine particles with at least 90% of the dry powder vaccine particles having an aerodynamic particle size of less than 5 microns;
- loading the vaccine formulation into a propellant gas-free dry powder inhaler;
- disbursing the vaccine material via air flow induced by inhalation;
- inhaling the vaccine formulation;
- and
- allowing at least some of the dry powder vaccine particles in the vaccine formulation to deposit on the pulmonary and the bronchial region of the lungs of the patient to provide both systemic and local mucosal immunity.
A method for creating an immune response in a patient, comprising the steps of:
- micronizing a vaccine material to form dry powder vaccine particles, with at least 90% of the dry powder vaccine particles having an aerodynamic particle size of less than 25 microns, while retaining at least 31% potency;
- blending the vaccine material with lactose particles larger than the vaccine particles into a blended formulation;
- loading the blended formulation into a propellant gas-free dry powder inhaler;
- and
- disbursing and inhaling the blended formulation, wherein the patient's inspiratory flow rate is less than 10 liters/minute, and wherein the inhaled dose is 3-25 mg.
Dependencies are inferred from the claim text.